Rethinking healthcare data governance
The recent UK Biobank breach created alarm within a medical sector embracing data digitalisation. The answer, says Ángel Alberich-Bayarri, is to apply better controls.
The recent UK Biobank data breach has understandably triggered concern about how medical data is accessed, shared and protected in the UK. Calls to restrict the use of health data, even for legitimate research and clinical innovation, are an instinctive natural reaction when trust is shaken. But if we respond to this incident by drawing the wrong conclusions, we risk undermining the very systems that protect patients and enable medical progress.
The UK Biobank was established in a very different era of data use. When it was conceived, health data was accessed by a smaller number of actors, through more limited technical channels, and often under assumptions that no longer hold. Today, medical data ecosystems are larger, more interconnected and more valuable. This in turn means they demand governance, oversight and infrastructure that is equally sophisticated.
What this incident exposes is not a fundamental flaw in healthcare data systems, but weaknesses in how governance has evolved within parts of the research and charity landscape. Oversight models that were sufficient a decade ago are no longer adequate when data is accessed at scale and through increasingly complex technical pathways.
It would be a mistake to extrapolate from this breach to NHS clinical systems. These environments operate under significantly tighter regulatory frameworks, with layered security controls, formal accountability structures and continuous monitoring. Access to patient data within clinical systems is governed by both policy and technical enforcement. This includes audit trails, role-based access and clear liability when standards are breached. That does not make them immune to risk, but it does make breaches of this nature far less likely to occur.
This distinction matters, because healthcare data sharing is not inherently reckless. On the contrary, responsible access to high-quality medical data underpins modern diagnostics, drug development and clinical decision-making. In laboratories, imaging departments and research settings across the UK, data-driven tools are already improving earlier detection, treatment personalisation and operational efficiency. Curtailing these activities in response to a governance failure elsewhere would be a disproportionate and ultimately harmful response.
The real question raised by the UK Biobank incident is how governance models must adapt to reflect today’s data realities. Safeguarding sensitive health data now requires more than well intentioned policies. It requires robust If we respond… by drawing the wrong conclusions, we risk undermining the very systems that protect patients and enable medical progress technical infrastructure, continuous oversight and leadership with the expertise to understand how data is accessed, processed and reused in practice.
In many cases, the greatest risks to health data arise not from its legitimate use in care or regulated research, but from environments where oversight, enforcement and technical safeguards have not kept pace with modern access patterns. This can include fragmented governance structures, insufficient auditing of third party access, or an over-reliance on trust rather than verification.
If we respond… by drawing the wrong conclusions, we risk undermining the very systems that protect patients and enable medical progress
For laboratory professionals and researchers, this moment should prompt a more nuanced conversation. Instead of asking whether medical data should be shared, we should be asking under what conditions, with what controls, and with what accountability. Strong governance does not mean less data use; it means safer, more transparent and more effective data use.
There is also a risk that public debate becomes overly focused on technology as the problem, rather than on how it is managed. Secure data platforms, centralised and federated Cloud infrastructures and privacy preserving analytics already exist and are in active use across healthcare. When deployed correctly, they reduce exposure while still enabling insight. However, no technology can compensate for unclear responsibility or weak oversight.
If there is a lesson to take from this incident, it is that data governance must be treated as a living system and not a static framework. As data volumes grow and use cases evolve, governance must be continually reassessed, stress tested and resourced accordingly. This is as true for research institutions as it is for healthcare providers and technology partners.
Restricting access to medical data may feel like the safest option in the short term, but it carries long-term costs. It slows research, limits innovation and ultimately delays benefits to patients. A more constructive response is to strengthen governance where it has fallen behind, while recognising that well regulated clinical and research systems already demonstrate that secure, ethical data use is possible.
Trust in health data systems is essential. Rebuilding it requires clarity, competence and accountability, not blanket assumptions that all data sharing is equally risky. The appropriate response to the UK Biobank breach is improved governance, not reduced ambition for data-driven healthcare
- Ángel Alberich-Bayarri is the founder and CEO of Quibim
